TITLE:
Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice
AUTHORS:
Somdet Srichairatanakool, Kanjana Pangjit, Chada Phisalaphong, Suthat Fucharoen
KEYWORDS:
Thalassemia; Iron Overload; Iron Chelator; Hydroxypyridinone; Lipid Peroxidation; Malondialdehyde
JOURNAL NAME:
Advances in Bioscience and Biotechnology,
Vol.4 No.2,
February
28,
2013
ABSTRACT: Desferrioxamine
(DFO), deferiprone (DFP) and deferasirox (DFX) are promising effective iron
chelators for the treatment of iron overload in b-thalassemia patients; nonetheless, their side effects
have also been reported. 3-Hydroxypyridinone derivatives are being developed as
a safer new chelator and in combined chelation therapy. We evaluated the
iron-chelating activity of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) in
iron-loaded C57BL6 mice. The feeding of a ferrocene-supplemented diet (Fe diet)
to mice resulted in iron overload, detectable plasma nontransferrin-bound iron
(NTBI) and labile plasma iron (LPI), and increases of red cell membrane iron,
plasma malondialdehyde (MDA) and excessive tissue iron deposits. Like DFP, the
CM1 lowered the levels of the membrane non-heme iron, the NTBI and LPI (p